Table 1.
Demographic and Clinical Characteristics of Patients with Immune-Mediated Colitis
| Characteristics | Value (n = 14) |
|---|---|
| Age (yr) | 64 (47–83) |
| Sex | |
| Male | 9 (64.3) |
| Female | 5 (35.7) |
| Body mass index (kg/m2) | 21.6 (16.0–25.3) |
| Smoking status | |
| Current | 1 (7.1) |
| Former | 8 (57.1) |
| Never | 5 (35.7) |
| Immune checkpoint inhibitor type | |
| PD-1 | 9 (64.3) |
| PD-L1 | 5 (35.7) |
| CTLA-4 | 0 |
| Cancer type | |
| Non-small cell lung carcinoma | 9 (64.3) |
| Pharyngeal carcinoma | 2 (14.3) |
| Renal cell carcinoma | 2 (14.3) |
| Esophageal carcinoma | 1 (7.1) |
| Cancer stage | |
| UICC III | 0 |
| UICC IV | 14 (100) |
| Clinical symptoms | |
| Stool frequency (times/day) | 9 (1–15) |
| Fever | 2 (14.3) |
| Bloody stool | 6 (42.9) |
| CTCAE grade of colitis | |
| 1 | 2 (14.3) |
| 2 | 1 (7.1) |
| 3 | 11 (78.6) |
| 4, 5 | 0 |
| Time to colitis onset (day) | 124 (12–459) |
| Other adverse events | |
| Endocrine | 1 (7.1) |
| Pancreatic | 1 (7.1) |
| Hepatic | 1 (7.1) |
| Serum C-reactive protein (mg/dL) | 4.7 (0.1–14.9) |
| Serum albumin (g/dL) | 3.3 (2.5–4.3) |
Values are presented as median (range) or number (%).
PD-1, programmed cell death receptor 1; PD-L1, PD-ligand 1; UICC, Union for International Cancer Control; CTCAE, Common Terminology Criteria for Adverse Events.